



August, 2009

Marketing Approval and forthcoming PBS listing for Tobra-day™ tobramycin 500mg in 5mL Injection

Phebra is pleased to announce that it has achieved marketing approval for Tobra-day™ in Australia. In addition, the company expects to have Tobra-day™ listed on the Australian Pharmaceutical Benefits Scheme effective as of November 2009.

Tobra-day™ is a high dose, preservative-free injection of tobramycin, used for the treatment and management of lung infections in people with cystic fibrosis caused by bacteria such as *Pseudomonas aeruginosa*. Cystic fibrosis is a genetic illness that affects over 3,600* Australians. Phebra was granted Orphan Drug Designation for Tobra-day™ by the Australian Therapeutic Goods Administration in April 2006.

“This is an important achievement for cystic fibrosis patients in this country”, said Dr Mal Eutick, CEO of Phebra, “Tobra-day™ was developed by Phebra as a high dose, preservative-free formulation of tobramycin for use in once-a-day antibiotic treatment regimens. We are pleased to bring this convenient and efficacious formulation to the Australian cystic fibrosis community. PBS listing ensures that patients with cystic fibrosis will have good access to this important life-saving medicine in our country”.

Supply of Tobra-day™ to Australian pharmaceutical wholesalers and hospitals is now available.

Phebra is an Australian speciality pharmaceutical company.

At Phebra, we create critical medicines that save and improve lives.

*Australian Institute of Health and Welfare, 2003

Tobra-day is a trademark of Phebra Pty Ltd

Phebra Pty Ltd
332 Burns Bay Road, Lane Cove NSW 2066 Australia
Locked Bag 3003, Hunters Hill NSW 2110 Australia
T +61 (0)2 9420 9199 F +61 (0)2 9420 9177 W www.phebra.com
ABN 77 695 661 635